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ABSTRACT 
We evaluated the influence of a 14 week endurance running programme on the 
exercise-induced release of high-sensitivity cardiac troponin T (hs-cTnT) and N-
terminal pro-brain natriuretic peptide (NT-proBNP). Fifty-eight untrained participants 
were randomised to supervised endurance exercise (14 weeks, 3-4 days/week, 120-240 
min/week, 65-85% of maximum heart rate) or a control group. At baseline and after the 
training programme hs-cTnT and NT-proBNP were assessed before and 5 min, 1 h, 3 h, 
6 h, 12 h, and 24 h after a 60 min maximal running test. Before training hs-cTnT was 
significantly elevated in both groups with acute exercise (P < 0.0001) with no between 
group differences. There was considerable heterogeneity in peak hs-cTnT concentration 
with the upper reference limit exceeded in 71% of the exercise tests. After training both 
baseline and post-exercise hs-cTnT were significantly higher compared to pre-training 
and the response of the control group (P = 0.008). Acute exercise led to a small but 
significant increase in NT-proBNP but this was not mediated by training (P = 0.121). In 
summary, a controlled endurance training intervention resulted in higher pre- and post-
exercise values of hs-cTnT with no changes in NT-proBNP.  
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INTRODUCTION 
Exercise promotes the elevation of serum troponins (cTnI and cTnT) and N-terminal 
pro-BNP (NT-proBNP), which are accepted parameters for the identification of cardiac 
damage and dysfunction. The post-exercise values of these biomarkers are often higher 
than the population's upper reference limit (URL; 27, 30). 
The clinical significance of the increase in cardiac-specific biomarkers after exercise in 
healthy subjects is unclear. Consequently, it is of interest to determine what personal or 
environmental factors mediate the exercise-induced release of cardiac biomarkers. One 
specific issue of interest has been the importance of training status. To date cross-
sectional studies have been inconsistent. Neilan et al. (20) reported higher values for 
cTnT and NT-proBNP in less well-trained runners after a marathon and this has been 
supported by others (5, 15, 19, 21, 39). Conversely, others have found no association 
between training status and biomarker release (4, 9, 27, 30, 38), and recent controlled 
and field based studies have even suggested higher values of hs-cTnT in those with high 
levels of training (unpublished, Legaz-Arrese et al., 24). Data for NT-proBNP are also 
equivocal with respect to training status (8, 25, 27, 30, 38).  
These discrepancies may be largely based on the limitations associated with cross-
sectional studies and the lack of control in field-based competitive studies as well as the 
number and timing of blood draws post-exercise. To date there are no longitudinal 
training interventions that have assessed exercise-induced cardiac biomarker release 
before and after an intervention. Consequently, we employed a randomized, controlled 
trial to investigate the effects of a 14-week endurance running training programme, 
compared to a control group with no intervention, on the release of high-sensitivity 
cTnT (hs-cTnT) and NT-proBNP consequent to a 60 min running time trial. We 
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hypothesized that training would have no significant effect on exercise-induced release 
of cardiac biomarkers. 
 
METHODS 
Participants and Design 
An invitation to participate in the study was sent to men and women (n = 323) between 
18 and 45 years of age from two University Faculties and a local company (Fig. 1). 
Sixty-nine potentially eligible participants responded and requested more information 
and all provided written informed consent after the protocol was explained to them. The 
Committee on Biomedical Ethics of the Aragon Government approved this study. 
Exclusion criteria were a significant personal or early family history of cardiovascular 
disease and/or abnormal electrocardiogram (ECG) at baseline examination. Further we 
excluded those already pursuing vigorous level of physical activity according to the 
self-administered, long format of the International Physical Activity Questionnaire 
(IPAQ) (3). The Spanish version (22) of the revised Physical Activity Readiness 
Questionnaire (PARQ) (35) was also administered to identify persons at risk for adverse 
events while exercising. Overall, 11 participants were excluded from the study because 
they performed vigorous physical activity on a regular basis according to the IPAQ and 
the remaining 58 participants were randomly assigned to either a training group or a 
control group according to a computer-generated randomization list (ratio 1.5:1). Seven 
participants in the training group (3 did not complete the exercise test; 4 did not 
attend<90% of training sessions) and 5 participants in the control group (2 did not 
complete the exercise test; 3 did not complete blood sampling) were not included in the 
final analysis. At completion of the study 28 subjects from the training group (22 men, 
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6 women) and 18 subjects from the control group (14 men, 4 women) were included in 
the intervention analysis. 
 
Experimental procedures  
All measurements were taken by examiners blinders to group assignment. During the 
first laboratory visit, subjects underwent anthropometric assessment. Body height was 
measured to the nearest 0.1 cm (SECA 225, SECA, Hamburg, Germany). Body mass 
was determined to the nearest 0.05 kg (SECA 861, SECA, Hamburg, Germany). 
Skinfold thickness was measured at the triceps, subscapular, supraspinal, abdominal, 
and front thigh and medial calf locations using Holtain skinfold callipers (Holtain, 
Crosswell, Crymych, UK). The fat percentage was obtained by the equation of Juhasz 
(41). 
In the second and third visit to the laboratory two exercise sessions of, 30 and 45 min 
duration, were performed to accustom subjects to running and pacing exercise intensity 
on a treadmill. Participants refrained from strenuous exercise for 48 h prior to the fourth 
laboratory visit during which they performed a 60 min “all-out” running “time trial” on 
a treadmill (Run Exicite 700, Technogym, Italia). The same “resting” period was 
established post-training. Prior to the test, the subjects completed a self-paced 5-min 
warm-up (HR 130 beats/min). Pairs of subjects competed side-by-side to provide some 
motivation and competition and strong verbal encouragement was provided during the 
test. Subjects were constantly aware of the time and distance covered. Water intake was 
allowed ad libitum. HR was recorded continuously during the tests via a Polar HR 
monitor (Polar Electro Oy, Kempele, Finland). The distance run in each test was 
recorded every 10 min. Pacing strategy was defined as the mean running velocity every 
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10 min. Immediately after the test participants rated the test for perceived exertion 
(RPE) (1). Venous blood samples were taken before, immediately after (5 min), and 1, 
3, 6, 12, and 24 h after exercise to assess serum hs-cTnT and NT-proBNP. All testing 
sessions occurred at 11:00 am in an air-conditioned laboratory with the temperature and 
relative humidity set at 20º C and 50%, respectively. 
 
Exercise training 
The 14-week endurance training programme followed a periodised progressive 
traditional design (10) consisting of five mesocycles with the programme divided into 
three training periods (Table 1). Briefly, in the preparatory period, the frequency and 
duration of training were increased and the intensity remained the same. In the first 
mesocycle of the competitive period, the duration and intensity were increased. The 
intensity continued to increase in the second mesocycle of this period, with a 
progressive decrease in the duration. In the taper period, the intensity was kept the same 
and duration was decreased. In all sessions, continuous running was performed on a flat 
course. From the second to the fifth mesocycle, sessions of higher and lower demand 
were rotated each week. Furthermore, regular stretching, core strengthening exercises 
and running drills were included in the sessions to minimise injury risk and improve 
running technique. Participants were provided with HR monitors. During each training 
session, intensities were individualised by prescribing training paces based on %HRmax 
according to different work areas (29). Each session was allowed a variation of ±3% of 
the %HRmax prescribed. All sessions were conducted in groups and were supervised by 
a coach. The control group was instructed not to change their habits regarding physical 
activities during the period and no subject performed vigorous levels of physical 
activity according to the IPAQ.  
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Blood Sampling Procedures 
Blood samples were drawn by repetitive venipuncture from an antecubital vein and 
quickly centrifuged. The serum and plasma were drawn off and stored at −80°C for later 
analysis. hs-cTnT was measured quantitatively with the new high-sensitive enzyme 
immunoassay based on electrochemiluminescence technology using the Cobas E 601 
analyzer (Roche Diagnostics, Penzberg, Germany). This assay has a range from 3 to 
10,000 ng/l with a lower limit of the blank of 3 ng/L. The coefficient of variation at a 
mean hs-cTnT level of 13.5 ng/L is 5.2%. The upper reference limit for hs-cTnT, 
defined as the 99th percentile of healthy participants, was 14 ng/L (7). NT-proBNP was 
analyzed in the serum with an Elecsys proBNP electrochemiluminescent immunoassay 
on the Roche Elecsys 1010 (Roche Diagnostics, Lewes, United Kingdom) with an 
analytical range of 5–35,000 ng/L and intra- and interassay imprecisions of 0.7–1.6% 
and 5.3–6.6%, respectively (2). The URL for NT-proBNP was considered to be 125 
ng/L (34). 
 
Statistical analysis 
Statistical analyses were performed using the IBM Statistical Package for the Social 
Sciences (IBM SPSS Statistics, v. 20.0 for WINDOWS). Cohort data are presented as 
the mean ± standard deviation unless otherwise stated. Kolmogorov-Smirnov tests were 
used to check for normal distribution and data for cTnI and NT-proBNP were log-
transformed prior to statistical testing. 3-way analysis of variance (ANOVA) was 
conducted with two within-subject factors (1-blood sampling time: pre-exercise, and 5 
min, 1, 3, 6, 12, and 24 h post-exercise; 2-training status: pre- vs. post-) and one 
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between-subject factor (group: control vs. training). Post-hoc Bonferroni tests were 
employed when appropriate. To support this analysis we performed 2-way ANOVAs on 
peak post-exercise hs-cTnT and peak NT-proBNP.  Finally, for each participant in each 
trial we calculated a delta score for both biomarkers from pre to peak-post exercise. 
The association between the exercise increase in both biomarkers and other relevant 
variables (e.g., baseline biomarker concentration, mean and max exercise HR) were 
assessed using bivariate Pearson’s product-moment correlation coefficients. The 
differences were considered significant if P < 0.05. 
 
RESULTS 
Impact of exercise training on subject characteristics and exercise data 
No between group differences existed at baseline so the groups were well matched at 
entry (Table 2). The training programme led to a decrease in weight and %fat (P < 
0.0001). After training, despite RPE being unchanged, there was an increase in speed in 
the 60 min running time trial (range: 1-2.70 km/h; P < 0.0001) as well as an increase in 
mean HR and %HRmax. No change in these variables was noted in the control group. 
Pacing strategy was similar in all subjects and was not influenced by the training 
programme. 
 
Impact of exercise training on hs-cTnT release 
A significant main effect of sampling time was observed for hs-cTnT, with increases 
compared to pre-exercise at 5 min, 1 h, 3 h, 6 h, 12 h, and 24 h post-exercise (P < 
0.0001) (Table 3). hs-cTnT was above the URL in 80% of participants. In most exercise 
tests, the maximum post-exercise value was observed at 3 h (83%) or 6 h (13%) and this 
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was largely consistent pre and post-training. Before the training programme, the two 
groups had similar pre-exercise (control group: median [range]; 3.0 [3.0-8.1]; training 
group: 3.6 [3.0-16.2] ng/L; P = 0.072) and peak post-exercise hs-cTnT (control group: 
14.7 [9.7-65.0]; training group: 16.6 [4.9-140.7] ng/L; P = 0.919). A significant group x 
training interaction was observed (P = 0.008), but no significant interaction between 
sampling time x training x group (P = 0.125). A significant training x group interaction 
was also observed for peak post-exercise hs-cTnT (P = 0.002). After training, hs-cTnT 
was lower in the control group at both pre (control group: 3.2 [3.0-7.5]; training group: 
5.1 [3.0-16.8] ng/L; P = 0.016) and peak post-exercise (control group: 17.8 [8.4-49.8]; 
training group: 27.7 [6.6-171.0] ng/L; P = 0.007). 
Peak post-exercise hs-cTnT was weakly associated with pre-exercise hs-cTnT only 
when all exercise tests were combined (r = 0.358, P < 0.0001). In the training group, the 
change in pre to peak post-exercise hs-cTnT were not associated with changes in 60 min 
time trial speed (r = -0.290, P = 0.886) or changes in mean HR (r = 0.079, P = 0.689). 
In the control group, a significant positive association was noted between pre and peak 
post-exercise hs-cTnT obtained at the two running time trials (r = 0.610, P = 0.007; r = 
0.742, P < 0.0001) suggesting some consistency/reliability in baseline and exercise hs-
cTnT response. Interestingly, despite intervention related changes in pre and peak post-
exercise hs-cTnT in the training group, the between test correlation for baseline and 
peak post-exercise hs-cTnT were also significant (r = 0.585, P = 0.001; r = 0.608, P = 
0.001). 
 
Impact of exercise training on NT-proBNP release 
There was increase in NT-proBNP from pre-exercise to 5 min, 1 h, 3 h, 6 h, 12 h, and 
24 h post-exercise (P < 0.0001; Table 4). In 15% of participants NT-proBNP values 
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exceeded the URL. Differences in the magnitude of peak data were accompanied by 
variable kinetics of NT-proBNP during recovery with the peak post-exercise values 
observed at 0 h (38%), 1 h (13%), 3 h (4%), 6 h (10%), 12 h (26%), and 24 h (9%). 
Prior to the intervention pre-exercise (control group: median [range]; 20.9 [7.1-87.7]; 
training group: 20.4 [8.4-123.4] ng/L; P = 0.685) and peak post-exercise values of NT-
proBNP (control group: 40.6 [16.4-169.3]; training group: 43.1 [17.4-234.5] ng/L; P = 
0.910) were similar between groups. The training programme had no effect on pre- or 
post-exercise NT-proBNP level (P = 0.121). 
In all tests peak post-exercise level of NT-proBNP was strongly associated with pre-
exercise concentration (r > 0.90). In the training group, NT-proBNP data were not 
associated with changes in 60 min time trial speed (r = -0.061, P = 0.758) or mean HR 
(r = 0.015, P = 0.940). Similar to hs-cTnT the pre and peak post-exercise data for NT-
proBNP were strongly correlated in the two time trials undertaken suggesting a high 
level of consistency in biomarker data (resting: control group, r = 0.899, P < 0.0001, 
training group: r = 0.694, P < 0.0001; peak post-exercise: control group: r = 0.874, P < 
0.0001, training group: r = 0.694, P < 0.0001). 
 
DISCUSSION 
The main findings of this study are that (1) a single 60-min bout of “all-out” running 
resulted in a significant increase in the both hs-cTnT and NT-proBNP with substantial 
variability in individual peak post-exercise data; (2) 14 weeks of endurance training 
resulted in higher pre-exercise and post-exercise values of hs-cTnT when compared to 
baseline testing and the control group; (3) endurance training had no impact on post-
exercise NT-proBNP or on the post-exercise kinetics of either biomarkers; and (4) pre- 
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and peak post-exercise levels of both biomarkers were strongly correlated between both 
tests suggesting high reproducibility in biomarker response to exercise. 
 
hs-TnT and NTproBNP release 
This study confirms that the exercise-induced release of hs-cTnT and NT-proBNP is not 
exclusive to ultra-endurance effort. Between study differences in exercise duration 
and/or the use of the new high sensitive assay for cTnT could explain why the 
percentage of subjects with cTn values above the URL was greater in this study (60 
min) than after a 30 min run (33). The release of NT-proBNP is largely associated with 
exercise duration and/volume (30, 31) with little influence exerted by exercise intensity 
(12, 30, 31). A shorter, 60 min run, could explain a lower percentage of subjects 
exceeding the URL of NT-proBNP in the current study. 
Our results also confirm marked individual variability in both biomarkers (16, 38). The 
high individual variability in the peak post-exercise response of hs-cTnT could not be 
explained by any control variable in this or other studies (38). This suggests that some 
currently unknown physiological factors make participants more or less likely to release 
cTn in response to exercise.  
Individual variability in the response to exercise of NT-proBNP was strongly related to 
the variability in pre-exercise values (11, 12, 23, 31). Despite this the current study 
observed a high degree of within subject consistency in peak post-exercise hs-cTnT 
release in both groups over their 2 trials, suggesting that hs-cTnT release is quite a 
robust phenomenon within any participant and that persists even after a training 
intervention that may alter the actual peak value of hs-cTnT. Whilst this supports some 
recent work with hs-cTnT (37, 40) it contradicts other field work that proposed that the 
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cTn (17, 18, 26) and NT-proBNP (37) response to exercise is random and not 
reproducible. Study to study differences are most likely due to methodological issues 
such as assay precision, environmental and exercise control as well as more frequent 
sampling. High reproducibility in the peak post-exercise values of NT-proBNP also 
confirms previous work (23, 26). On-going work should determine the causes of the 
high between subject variability in quantitative cTn and NT-proBNP release.   
 
Kinetics of hs-TnT and NTproBNP release 
This study provided a comprehensive analysis of individual post-exercise kinetics for 
hs-cTnT and NT-proBNP. For hs-cTnT, most subjects showed the peak post-exercise 
value at 3 h which is consistent with the only previous hs-cTnT study (38). Several 
studies have considered it sufficient to take a single blood sample 3-4 h post-exercise to 
record the post-exercise cTn peak (6, 21, 37). This viewpoint is only partially supported 
by the results of this study as 15% of subjects obtain the peak post-exercise value 6 h 
after the 60 min run. The discrepancy between studies might be attributed to differences 
in assay precision and the number of blood sample points after the start of exercise. 
Importantly, the kinetics data from the current study is somewhat different to that 
observed for cTn in acute myocardial infarction (36). At 24 h post-exercise all hs-cTnT 
values were close to pre-exercise levels. In addition, the increase in hs-cTnT occurred in 
the absence of clinical signs and symptoms. This suggests that post-exercise hs-cTnT 
level may be reflect a physiological, rather than pathological, response to exercise 
stimulus. The hypothesis that has been proposed is that endurance exercise causes an 
increase in membrane permeability due to the physiological stress placed on the cell, 
inducing a transient cytosolic leakage due to membrane damage, rather than 
cardiomyocyte necrosis (32) although this requires empirical support. 
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The post-exercise kinetics of NT-proBNP has received less attention (38). Our data 
suggest that the kinetics for NT-proBNP are more diverse than for hs-cTnT with an 
incomplete recovery to baseline at 24 hr post-exercise. The elevation in NT-proBNP at 
24 h could reflect a temporary reduction in kidney function and changes in cardiac 
function (38), but this requires further study.  
 
Effect of exercise training on hs-TnT and NTproBNP values 
Our main objective was to determine whether the hs-cTnT and NT-proBNP response to 
exercise is mediated by a change in training status. We observed higher baseline and 
peak post exercise values for hs-cTnT after 14 weeks of running training that also 
differentiated this group from a control cohort. This supports some previous cross-
sectional data from athletes of different training status (unpublished, Legaz-Arrese et 
al., 24) but does contradict past field-based studies of runners with higher and lower 
self-report training volume (e.g. 20). The assay precision and the method used to 
quantify the level of training may also be a confounding factor in the relationship 
observed in previous studies. In the largest case series data in marathoners by Fortescue 
et al. (5) noted that the runners with less prior experience in marathon running were 
more likely to have cTnT increases. They also found no relationship between race time 
and an increase in cTnT, suggesting that the number of previous marathons may not be 
the most appropriate way to quantify the current level of training. Furthermore, the 
authors indicated no significant relationship between the release of cTnT and average 
training pace or average miles run per week during the last 3 months. In the same 
direction, a multiple regression analysis demonstrated marathon experience was a 
significant predictor of post-marathon hs-cTnT (19). Once again, the authors did not 
establish a relationship between marathon time and the release of hs-cTnT and did not 
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gather other data on the level of training of the athletes. The association observed by 
Nie et al. (21) and Tian et al. (39) between the number of years of training and cTnT or 
cTnI release after a half-marathon in adolescent subjects was weak and could have been 
influenced by the maturity status of the adolescents. Moreover, in neither of these 
studies did the authors observe a relationship for other indicators of the level of training, 
such as weekly training distance. Finally, using a prospective-study design, Mehta et al. 
(15) revealed that average miles run per week in the last 3 years (an indicator of 
previous training experience) was negatively associated with post-marathon cTnI 
release. No association, however, was observed for the current training status (miles run 
per week in the last 4 month) or for the race time. 
Training resulted in a performance improvement in the 60 min running time trial at the 
same time as baseline and peak post-exercise hs-cTnT were increased. It was, therefore, 
somewhat surprising to see performance and hs-cTnT changes were not strongly 
associated. Whether this reflects a limited range of change in performance data or a lack 
of a systematic effect of training status change is difficult to determine. In field-based 
studies, where numerous factors are not controlled, and performance and biomarker 
differences between groups may be more extensive a closer association between 
training status and hs-cTnT release may be more apparent. 
A number of theories could be proposed to explain higher hs-cTnT after training. 
Although speculative, higher pre-exercise and post-exercise hs-cTnT values after 
training could be a consequence of an adaptive process occurring in the heart due to the 
exercise training stimulus. Heart size is associated with performance (14), and its 
adaptation is greater in less trained subjects (13). Recent work from Saravia et al. (24) 
have suggested a link between higher levels of inflammation and increased cTn in faster 
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marathon runners. Future work should evaluate these hypotheses in appropriate research 
designs. 
We observed that training had no influence on the value of NT-proBNP or on the 
kinetics of either biomarker. Few studies have established the relationship between the 
level of training and the exercise-induced release of NT-proBNP. Like Neilan et al. 
(20), Serrano-Ostáriz et al. (30) in road cyclists and Hermann et al. (8) in marathoners 
also observed a weak relationship between the level of training and the release of NT-
proBNP. This relationship disappeared when differences between athletes in the 
duration of effort were controlled. In other recent studies the relationships have not been 
significant (12, 23, 27, 28, 38). 
 
Limitations, future research and implications of this study 
We selected previously untrained subjects because of the difficulty in establishing both 
control periods and marked training change in athletes. For this reason, our work was 
limited to assessing the response of the release of cardiac biomarkers after an effort of 
relatively short duration (60 min). Our results, and their clinical impact, cannot be 
directly extrapolated to the effects of much more demanding training programmes such 
as those performed by elite athletes competing in marathons, road cycling, and 
triathlons. Many field-based studies, however, recruit amateur athletes who present with 
biomarker responses similar to that observed in the current study and these athletes 
represent a much bigger and diverse proportion of mass-participation endurance events 
than elite athletes. The clinical importance therefore is more likely to be related to the 
amateur athlete presenting after an endurance event with a raised cardiac biomarker. 
Clearly appropriate “work-up” of any elevated hs-cTnT is important but this must also 
recognize prior exercise as a key component. 
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The relationship between the exercise-induced release of cardiac biomarkers and the 
factors determinants of running performance (e.g. VO2max) might be useful to evaluate 
high individual variability in biomarker release. Future work should also recruit a larger 
sample of female athletes and address the issue of whether the phase of the menstrual 
cycle could mediate biomarker release.  
In conclusion, a 14-week endurance running training programme led to higher pre-
exercise and peak post-exercise values of hs-cTnT but did not change NT-proBNP or 
the kinetics of either biomarker. The change in hs-cTnT after training was not directly 
related to changes in performance or the cardiovascular stress of a 60 min exercise 
stimulus after the intervention. The kinetics of hs-cTnT appearance suggests that the 
exercise-induced release is a physiological process with no known clinical 
consequences. Clinicians should be aware that the release of cardiac biomarkers is not 
exclusive to long-term strenuous efforts and values above the URL for hs-cTnT can be 
observed in most subjects. 
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Figure Legends 
Fig. 1. The flow of participants throughout the trial. 
 
Fig. 2. Individual data points of hs-cTnT (ng/L) in the control group (a) baseline, (b) 
post-training ] and in the training group (c) basaline, (d) post-training ] before exercise 
(PRE) and 5 min, 1 h, 3 h, 6 h, 12 h, and 24 h (0HR, 1HR, 3HR, 6HR, 12HR, 24HR, 
respectively) after a 60 min maximal running trial. The horizontal dotted line is the 
upper reference limit (99th percentile) at 14 ng/L. 
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Table 1. Characteristics of the training programme 
Period Mesocycle Week 
Session 1 
(min-
%HRmax) 
Session 2 
(min-
%HRmax) 
Session 3 
(min-
%HRmax) 
Session 4 
(min-
%HRmax) 
Duration/week 
(min) 
Intensity/week 
(%HRmax) 
Preparatory 
1 
1 40 min-65% 40 min-65% 40 min-65%  120 65 
2 40 min-65% 40 min-65% 40 min-65%  120 65 
3 50 min-65% 50 min-65% 50 min-65%  150 65 
4 50 min-65% 50 min-65% 50 min-65%  150 65 
2 
5 50 min-65% 40 min-65% 50 min-65% 40 min-65% 180 65 
6 50 min-65% 40 min-65% 50 min-65% 40 min-65% 180 65 
Competition 
3 
7 60 min-70% 40 min-65% 60 min-70% 40 min-65% 200 65-70 
8 60 min-70% 40 min-65% 60 min-70% 40 min-65% 200 65-70 
9 70 min-75% 40 min-70% 70 min-75% 40 min-70% 220 70-75 
10 80 min-75% 40 min-70% 80 min-75% 40 min-70% 240 70-75 
4 
11 70 min-80% 40 min-75% 70 min-80% 40 min-75% 220 75-80 
12 60 min-85% 40 min-80% 60 min-85% 40 min-80% 200 80-85 
Taper 5 
13 50 min-85% 40 min-80% 50 min-85% 40 min-80% 180 80-85 
14 40 min-85% 40 min-80% 40 min-85% 40 min-80% 160 80-85 
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Table 2. Subject characteristics and exercise data Pre and Post training 
 Control group (n = 18) Exercise group (n = 28) 
 Pre Post Pre Post 
Subject characteristics 
    Age 30.6 ± 8.7 -------- 29.9 ± 9.9 -------- 
    Height, m 1.76 ± 0.09 -------- 1.76 ± 0.06 -------- 
    Weight, kg 69.9 ± 9.4 69.1 ± 9.8* 71.1 ± 8.2 67.9 ± 8.5*† 
    Body fat, % 11.6 ± 4.6 11.1 ± 4.8* 11.8 ± 4.4 9.9 ± 4.4*† 
    Maximum HR, bpm 187 ± 11 187 ± 11 189 ± 8 188 ± 8 
60 min performance 
    Velocity, km/h 10.5 ± 1.1 10.7 ± 0.9 10.4 ± 1.1 12.1 ± 0.9*† 
    Mean HR, bpm 161 ± 11 163 ± 11 160 ± 11 166 ± 11*† 
    % HRmax 86 ± 3 87 ± 4 85 ± 4 88 ± 4* † 
    RPE 8.5 ± 0.8 8.8 ± 0.8 8.4 ± 0.8 8.7 ± 1.1 
Values are presented as means ± SD. *significantly different from pre-training; †significantly different from control group at Post training.  
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Table 3. hs-cTnT concentrations after 60 min of high-intensity running Pre and Post training 
 Control group (n = 18) Exercise group (n = 28) ANOVA P-values 
 Pre Post Pre Post  
Pre-exercise 
3.0 (3.0-8.1) 
(0) 
3.2 (3.0-7.5) 
(0) 
3.6 (3.0-16.2) 
(4) 
5.1 (3.0-16.8) 
(7) 
Time <0.0001 
5 min 
5.1 (3.0-10.8) 
(0) 
5.3 (3.3-12.2) 
(0) 
6.8 (3.0-39.4) 
(14) 
9.8 (3.0-28.7) 
(14) 
Training 0.003 
1 h 
9.5 (5.2-23.7) 
(11) 
9.6 (3.8-22.3) 
(17) 
10.0 (3.0-36.5) 
(25) 
13.6 (6.1-67.9) 
(46) 
Group 0.073 
3 h 
14.2 (9.7-57.2) 
(50) 
16.6 (8.4-49.8) 
(67) 
16.1 (4.9-140.7) 
(64) 
26.3 (6.6-171.0) 
(89) 
Time x Group 0.512 
6 h 
13.0 (7.0-65.0) 
(44) 
13.4 (5.7-41.2) 
(50) 
15.2 (3.5-97.7) 
(54) 
18.9 (6.4-156.0) 
(79) 
Training x Group 0.008 
12 h 
6.7 (3.7-58.1) 
(11) 
8.3 (4.0-24.7) 
(22) 
9.2 (3.0-39.1) 
(29) 
11.0 (4.6-68.5) 
(32) 
Time x Training 0.123 
24 h 
4.3 (3.0-33.2) 
(11) 
4.9 (3.0-12.5) 
(0) 
6.3 (3.0-19.3) 
(7) 
6.7 (3.0-36.2) 
(11) 
Time x Training x Group 0.125 
Data are median (range) with the percentage of subjects with hs-cTnT values exceeding the URL in parentheses. 
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Table 4. NT-proBNP concentration after 60 min of high-intensity running Pre and Post training 
 Control group (n = 18) Exercise group (n = 28) ANOVA P -value 
 Pre Post Pre Post  
Pre-exercise 
20.9 (7.1-87.7) 
(0) 
18.7 (6.0-121.0) 
(0) 
20.4 (8.4-123.4) 
(0) 
21.1 (6.7-73.0) 
(0) 
Time <0.0001 
5 min 
36.0 (11.0-169.3) 
(6) 
36.3 (9.8-215.2) 
(6) 
34.9 (11.1-215.7) 
(7) 
40.7 (9.3-142.0) 
(7) 
Training 0.299 
1 h 
28.4 (11.2-147.5) 
(11) 
30.8 (10.4-196.7) 
(11) 
32.9 (12.5-234.5) 
(7) 
36.0 (10.9-178.6) 
(7) 
Group 0.896 
3 h 
26.7 (9.9-139.3) 
(6) 
29.1 (9.1-187.4) 
(6) 
27.2 (12.6-207.7) 
(4) 
33.5 (11.1-204.7) 
(7) 
Time x Group 0.431 
6 h 
31.6 (12.3-148.4) 
(17) 
29.6 (9.9-142.7) 
(6) 
31.3 (11.9-135.0) 
(4) 
31.9 (17.0-127.5) 
(4) 
Training x Group 0.121 
12 h 
29.5 (16.4-158.9) 
(17) 
33.1 (10.8-121.2) 
(0) 
29.3 (9.1-103.4) 
(0) 
35.1 (16.0-105.3) 
(0) 
Time x Training 0.207 
24 h 
26.4 (10.5-99.7) 
(0) 
27.1 (10.5-100.4) 
(0) 
24.1 (9.1-55.9) 
(0) 
26.7 (11.4-103.8) 
(0) 
Time x Training x Group 0.540 
Data are median (range) with the percentage of subjects with NT-proBNP values exceeding the URL in parentheses. 
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Fig. 1. The flow of participants throughout the trial. 
 
 
 
 
 
 
 
 
 
 
 
  
Subjects invited (n=323)
University students and workers from a local company
Informed consent (n=69)
Excluded
- Refused (n=254)
Randomized (n=58)
Excluded
- Not meeting inclusion (n=11)
Assigned to exercise group (n=35) Assigned to control group (n=23)
Completed trial (n=28) Completed trial (n=18)
Drop out during the exercise test (n = 2)
Not attending assessment (n=3)
Drop out during the exercise test (n=3)
Not attending <90% trial (n=4)
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Fig. 2. Individual data points of hs-cTnT (ng/L) in the control group (a) baseline, (b) post-training ] and in the training group (c) 
basaline, (d) post-training ] before exercise (PRE) and 5 min, 1 h, 3 h, 6 h, 12 h, and 24 h (0HR, 1HR, 3HR, 6HR, 12HR, 24HR, 
respectively) after a 60 min maximal running trial. The horizontal dotted line is the upper reference limit (99th percentile) at 14 ng/L. 
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